[Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
The antiemetic efficacy of dexamethasone (Dexaven) was examined in patients with breast cancer during chemotherapy CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in comparison with patients treated identically but without dexamethasone. Comparison of the revealed statistically significant lower nausea incidence (p < 0.025) and lower vomiting incidence (p < 0.025) in the group of patients receiving dexamethasone. The results confirm value of dexamethasone as an effective and safe antiemetic agent using during chemotherapy CMF.
Domaradzka-Woźniak
A
A
Miejskiej Przychodni Onkologicznej, Gdańsku.
Wojtacki
J
J
Dziewulska-Bokiniec
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000009:adverse effects; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D003907:Dexamethasone; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Zastosowanie deksametazonu jako leku przeciwwymiotnego u chorych na raka sutka leczonych wg schematu CMF.